Erasmus School of Health Policy & Management
Visiting fellow | Health Technology Assessment (HTA)
- vangils@eshpm.eur.nl
More information
Work
- Renaud J.S.D. Heine, Ron H.J. Mathijssen, Floor A.J. Verbeek, Chantal Van Gils & Carin A. Uyl-de Groot (2024) - Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands - Value in Health, 27 (10), 1367-1372 - doi: 10.1016/j.jval.2024.06.003 - [link]
- L Mohseninejad, Chantal van Gils, Carin Uyl - de Groot, E Buskens & TL (Talitha) Feenstra (2015) - Evaluation of Patient Registries Supporting Reimbursement Decisions: The Case of Oxaliplatin for Treatment of Stage III Colon Cancer - Value in Health, 18, 84-90 - doi: 10.1016/j.jval.2014.10.008 - [link]
- Lucas Goossens, Ken Redekop & Chantal van Gils (2015) - Noncollapsibility and Censoring: What's the Bias in Estimating Effects on Survival? - Epidemiology, 26 (1), e1-e2 - doi: 10.1097/EDE.0000000000000197
- Chantal van Gils, Saskia de Groot, Siok Swan Tan, Ken Redekop, M Koopman, CJ Punt & Carin Uyl - de Groot (2014) - Real-world resource use and costs of adjuvant treatment for stage III colon cancer - European Journal of Cancer Care, 24 (3), 321-332 - doi: 10.1111/ecc.12154 - [link]
- Naomi Linden, Chantal van Gils, CP Pescott, J Buter, MR Vergeer & Carin Uyl - de Groot (2014) - Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck - European Archives of Oto-Rhino-Laryngology, 272 (8), 2007-2016 - doi: 10.1007/s00405-014-3106-3
- Chantal van Gils (2013) - Real-world cost-effectiveness - [link]
- Naomi Linden, Chantal van Gils, CP Pescott, J Buter & Carin Uyl - de Groot (2013) - Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial results - European Archives of Oto-Rhino-Laryngology, 271 (6), 1673-1678 - doi: 10.1007/s00405-013-2646-2 - [link]
- Chantal van Gils, Saskia de Groot, Ken Redekop, M Koopman, CJA Punt & Carin Uyl - de Groot (2013) - Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence - Pharmacoeconomics (Print), 31 (8), 703-718 - doi: 10.1007/s40273-013-0061-6 - [link]
- Margreet Franken, Chantal van Gils, JG (Jennifer G.) Gaultney, GO Delwel, W Goettsch, PC Huijgens, Adri Steenhoek, CJA Punt, M Koopman, Ken Redekop & Carin Uyl - de Groot (2013) - Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands - European Journal of Cancer, 49, 8-16 - doi: 10.1016/j.ejca.2012.06.010 - [link]
- Chantal van Gils, M Koopman, L (Linda) Mol, Ken Redekop, Carin Uyl - de Groot & CJA Punt (2012) - Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in The Netherlands - Acta Oncologica, 51, 57-64 - doi: 10.3109/0284186X.2011.633930 - [link]
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2024
- Course Code
- GW4555M
Master Thesis HE
- Year Level
- master, master
- Year
- 2024
- Course Code
- GW4592M
